AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27638294 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic (0.25% bupivacaine)
Number of subjects: 74
Study 24965167 — intervention group
Group type: COMPARATOR
Intervention: Losartan (LS) 50 mg
Number of subjects: 102
Study 24965167 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Losartan (LS) 50 mg and Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 102
Study 22008090 — intervention group
Group type: EXPERIMENTAL
Intervention: With calcium channel blocker (CCB) (n = 1807)
Number of subjects: 3031
Study 22008090 — intervention group
Group type: EXPERIMENTAL
Intervention: With CCB plus valsartan (n = 773)
Number of subjects: 3031
Study 22008090 — intervention group
Group type: EXPERIMENTAL
Intervention: Without CCB plus valsartan (n = 744)
Number of subjects: 3031
Study 19506172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex gum (4 mg, unflavored) for 4 weeks before and 8 weeks after the target quit date.
Number of subjects: 314
Study 19506172 — intervention group
Group type: COMPARATOR
Intervention: Usual care with nicotine gum for 8 weeks after the quit date.
Number of subjects: 314
Study 17474951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral State Index (CSI)
Number of subjects: 20
Study 17474951 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐line ARX (AAI)
Number of subjects: 20
Study 14709943 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 253
Study 14709943 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at high doses
Number of subjects: 253
Study 14709943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 11463009 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic bilateral total mastectomy
Number of subjects: 139
Study 11463009 — intervention group
Group type: COMPARATOR
Intervention: Regular surveillance (Control)
Number of subjects: 139
Study 9640570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) applied during trabeculectomy
Number of subjects: 59
Study 9640570 — intervention group
Group type: COMPARATOR
Intervention: No Mitomycin-C (MMC) applied during trabeculectomy
Number of subjects: 59
Study 9640570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) applied during triple procedure
Number of subjects: 59
Study 9640570 — intervention group
Group type: COMPARATOR
Intervention: No Mitomycin-C (MMC) applied during triple procedure
Number of subjects: 59
Study 8956477 — intervention group
Group type: EXPERIMENTAL
Intervention: 280 mg GLY-GLN per kg body weight/day for 4 days
Number of subjects: 9
Study 8956477 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg GLY-GLN per kg body weight/day for 4 days
Number of subjects: 9
Study 8956477 — intervention group
Group type: EXPERIMENTAL
Intervention: 570 mg GLY-GLN per kg body weight/day for 4 days
Number of subjects: 9
Study 8956477 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition without GLY-GLN supplementation
Number of subjects: 9
Study 1903813 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenothrin lotion
Number of subjects: 101
Study 1903813 — intervention group
Group type: COMPARATOR
Intervention: Malathion lotion
Number of subjects: 101
Study 1903813 — intervention group
Group type: COMPARATOR
Intervention: Carbaryl lotion
Number of subjects: 101
Study 6998600 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxicromil, administered orally before antigen challenge, dosage not specified, duration of action studied for at least 12 hours.
Number of subjects: 10
Study 30602342 — intervention group
Group type: EXPERIMENTAL
Intervention: RCEA ACX (°)
Number of subjects: 325
Study 31103124 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RG)
Number of subjects: 60
Study 31103124 — intervention group
Group type: COMPARATOR
Intervention: Sophrology (SG)
Number of subjects: 60
Study 31103124 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 60
Study 27743470 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM rehabilitation program
Number of subjects: 53
Study 27743470 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 53
Study 23179140 — intervention group
Group type: EXPERIMENTAL
Intervention: Single group education session on APAP therapy
Number of subjects: 146
Study 23179140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education session)
Number of subjects: 146
Study 23179140 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education session
Number of subjects: 146
Study 20443014 — intervention group
Group type: EXPERIMENTAL
Intervention: Angeliq (drospirenone 2 mg and estradiol 1 mg)
Number of subjects: 32
Study 19264047 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent pressure ulcers (PrUs)
Number of subjects: 24
Study 19264047 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 24
Study 16895884 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 microg vitamin B-12
Number of subjects: 195
Study 16895884 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 microg vitamin B-12 + 400 microg folic acid
Number of subjects: 195
Study 16895884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 14756978 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly meeting (WM) group
Number of subjects: 98
Study 14756978 — intervention group
Group type: EXPERIMENTAL
Intervention: Correspondent (CR) group
Number of subjects: 98
Study 14756978 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) group
Number of subjects: 98
Study 11716665 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician recommendation of hormone replacement therapy (HRT)
Number of subjects: 581
Study 9056061 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (80 g total dose, administered starting 4 h after sodium valproate)
Number of subjects: 7
Study 9056061 — intervention group
Group type: COMPARATOR
Intervention: Control (no activated charcoal)
Number of subjects: 7
Study 8419816 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (750 mg three times daily) plus Metronidazole (500 mg three times daily) for 12 days, along with Ranitidine (300 mg each night) for 6 or 10 weeks.
Number of subjects: 104
Study 8419816 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 days, along with Ranitidine (300 mg each night) for 6 or 10 weeks.
Number of subjects: 104
Study 3465793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental insurance plans requiring no cost sharing
Number of subjects: 264
Study 3465793 — intervention group
Group type: COMPARATOR
Intervention: Cost-sharing dental insurance plans
Number of subjects: 264
Study 31490311 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% garlic ointment
Number of subjects: 17
Study 31490311 — intervention group
Group type: COMPARATOR
Intervention: Vaseline
Number of subjects: 17
Study 29735088 — intervention group
Group type: EXPERIMENTAL
Intervention: Red beet juice
Number of subjects: 12
Study 29735088 — intervention group
Group type: EXPERIMENTAL
Intervention: Crunchy slices
Number of subjects: 12
Study 29735088 — intervention group
Group type: COMPARATOR
Intervention: Both products
Number of subjects: 12
Study 27382257 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 64
Study 27382257 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 64
Study 24824629 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg lithium carbonate
Number of subjects: 10
Study 24824629 — intervention group
Group type: EXPERIMENTAL
Intervention: 1350 mg lithium carbonate
Number of subjects: 10
Study 24824629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23121768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol locks (70% ethanol, once per week)
Number of subjects: 49
Study 23121768 — intervention group
Group type: COMPARATOR
Intervention: Heparin locks (thrice per week)
Number of subjects: 49
Study 20130408 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed buprenorphine tablets
Number of subjects: 16
Study 20130408 — intervention group
Group type: COMPARATOR
Intervention: Whole buprenorphine tablets
Number of subjects: 16
Study 20130408 — intervention group
Group type: COMPARATOR
Intervention: Crushed placebo tablets
Number of subjects: 16
Study 20130408 — intervention group
Group type: COMPARATOR
Intervention: Whole placebo tablets
Number of subjects: 16
Study 18816321 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) booklet
Number of subjects: 31
Study 16114153 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 30% dextrose (2 ml)
Number of subjects: 52
Study 16114153 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (2 ml)
Number of subjects: 52
Study 11799504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 15
Study 11799504 — intervention group
Group type: COMPARATOR
Intervention: Waking state
Number of subjects: 15
Study 10067266 — intervention group
Group type: COMPARATOR
Intervention: SK (Streptokinase) group (3750 IU/hour)
Number of subjects: 88
Study 10067266 — intervention group
Group type: EXPERIMENTAL
Intervention: SK-Plg (Streptokinase + exogenous lys-plasminogen 7.5 mg)
Number of subjects: 88
Study 10067266 — intervention group
Group type: EXPERIMENTAL
Intervention: SK-Plg group
Number of subjects: 88
Study 8638984 — intervention group
Group type: EXPERIMENTAL
Intervention: EHRZ (Ethambutol, HRZ)
Number of subjects: 907
Study 8638984 — intervention group
Group type: COMPARATOR
Intervention: SHRZ (Streptomycin, HRZ)
Number of subjects: 907
Study 1672921 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 30
Study 1672921 — intervention group
Group type: COMPARATOR
Intervention: Temazepam
Number of subjects: 30
Study 1672921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7069582 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution (1 g of ascorbic acid)
Number of subjects: 4
Study 7069582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet (1 g of ascorbic acid)
Number of subjects: 4
Study 7069582 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed-release capsule (1 g of ascorbic acid)
Number of subjects: 4
Study 7069582 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dose of ascorbic acid
Number of subjects: 4
Study 30503849 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Circuit Resistance Training (CRT) for 8 weeks (3 times/week, 65-85% of 1 repetition maximum)
Number of subjects: 30
Study 30503849 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Circuit Resistance Training (CRT)
Number of subjects: 30
Study 30503849 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 28069563 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioural therapy (CBT) plus treatment as usual (TAU)
Number of subjects: 220
Study 28069563 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 220
Study 25481862 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular chocolate chip cookie
Number of subjects: 300
Study 25481862 — intervention group
Group type: COMPARATOR
Intervention: Sugar-free chocolate chip cookie
Number of subjects: 300
Study 23806610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program for 6 months
Number of subjects: 50
Study 23806610 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise program for 6 months
Number of subjects: 50
Study 20646862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-precision radiotherapy (three-dimensional conformal radiotherapy or intensity-modulated radiation therapy)
Number of subjects: 60
Study 20646862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-precision radiotherapy
Number of subjects: 60
Study 19770437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanned children
Number of subjects: 131
Study 19770437 — intervention group
Group type: COMPARATOR
Intervention: Minimally tanned children
Number of subjects: 131
Study 19770437 — intervention group
Group type: COMPARATOR
Intervention: Darker-skinned white children
Number of subjects: 131
Study 17520888 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxypine (150 mg every day for 14 days)
Number of subjects: 0
Study 17520888 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (300 mg a day for 14 days)
Number of subjects: 0
Study 15355528 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPS implementation programme (study group)
Number of subjects: 129
Study 15355528 — intervention group
Group type: COMPARATOR
Intervention: Regular 3-day documentation course (control group)
Number of subjects: 129
Study 11972430 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-course glucocorticoids
Number of subjects: 0
Study 11972430 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated courses of glucocorticoids
Number of subjects: 0
Study 11972430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to glucocorticoids
Number of subjects: 0
Study 9587910 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave radiation exposure (6-12 GHz)
Number of subjects: 0
Study 9587910 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8308619 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam alone
Number of subjects: 207
Study 8308619 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-midazolam
Number of subjects: 207
Study 8308619 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam
Number of subjects: 207
Study 8308619 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam-methohexital
Number of subjects: 207
Study 8308619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 3370199 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum aspiration
Number of subjects: 97
Study 3370199 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemeprost (1 mg vaginal pessary every 3 h for up to 5 pessaries)
Number of subjects: 97
Study 3370199 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (150 mg per day for 4 days)
Number of subjects: 97
Study 3370199 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (150 mg per day for 4 days) plus Gemeprost (1 mg on day 3)
Number of subjects: 97
Study 3370199 — intervention group
Group type: COMPARATOR
Intervention: RU 486 alone
Number of subjects: 97
Study 30798472 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide 500 mg
Number of subjects: 63
Study 30798472 — intervention group
Group type: COMPARATOR
Intervention: Valproate sodium 400 mg
Number of subjects: 63
Study 31102145 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant bevacizumab with oxaliplatin-based chemotherapy
Number of subjects: 1226
Study 31102145 — intervention group
Group type: COMPARATOR
Intervention: Standard oxaliplatin-based chemotherapy regimens
Number of subjects: 1226
Study 28916436 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (solifenacin 5mg and mirabegron 25mg, increased to 50mg at week 4)
Number of subjects: 2110
Study 28916436 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5mg
Number of subjects: 2110
Study 28916436 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 10mg
Number of subjects: 2110
Study 26126306 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use negative pressure wound therapy (NPWT) system
Number of subjects: 110
Study 26126306 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (historical)
Number of subjects: 110
Study 23932641 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography (CTA)
Number of subjects: 291
Study 21057704 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-TF activity before chemotherapy
Number of subjects: 122
Study 21057704 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-TF activity after chemotherapy
Number of subjects: 122
Study 21057704 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-TF activity in patients who developed VTE
Number of subjects: 122
Study 21057704 — intervention group
Group type: COMPARATOR
Intervention: MP-TF activity in patients who did not develop VTE
Number of subjects: 122
Study 18455586 — intervention group
Group type: EXPERIMENTAL
Intervention: Total arterial revascularization (161 patients)
Number of subjects: 331
Study 18455586 — intervention group
Group type: COMPARATOR
Intervention: Conventional revascularization (170 patients)
Number of subjects: 331
Study 17006119 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% endotracheal tube cuff lignocaine
Number of subjects: 82
Study 17006119 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/kg intravenous lignocaine
Number of subjects: 82
Study 15002860 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to Mozart's Sonata for Two Pianos
Number of subjects: 0
Study 15002860 — intervention group
Group type: EXPERIMENTAL
Intervention: Various conditions (not specified)
Number of subjects: 0
Study 15002860 — intervention group
Group type: COMPARATOR
Intervention: Verbal Reasoning condition
Number of subjects: 0
Study 15002860 — intervention group
Group type: COMPARATOR
Intervention: Spatial Reasoning condition
Number of subjects: 0
Study 11052464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone meal powder (BEC)
Number of subjects: 12
Study 11052464 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CAC)
Number of subjects: 12
Study 8804333 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment
Number of subjects: 97
Study 8804333 — intervention group
Group type: COMPARATOR
Intervention: Episodic infusion
Number of subjects: 97
Study 8804333 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic care
Number of subjects: 97
Study 1535359 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Treatment (SMT)
Number of subjects: 45
Study 1535359 — intervention group
Group type: COMPARATOR
Intervention: Sham Manipulation
Number of subjects: 45
Study 6386484 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg etozolin (E)
Number of subjects: 17
Study 6386484 — intervention group
Group type: COMPARATOR
Intervention: 40 mg furosemide (F)
Number of subjects: 17
Study 31953630 — intervention group
Group type: EXPERIMENTAL
Intervention: Go intervention group (IG) attending 12 Go lessons
Number of subjects: 18
Study 31953630 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) attending health education lectures
Number of subjects: 18
Study 31397289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 10 mg/kg
Number of subjects: 251
Study 31397289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 3 mg/kg
Number of subjects: 251
Study 31397289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 1 mg/kg
Number of subjects: 251
Study 31397289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 31397289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab (all doses)
Number of subjects: 251
Study 28151742 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester weight gain trajectory (measured in SD increases above predicted gain)
Number of subjects: 124590
Study 28151742 — intervention group
Group type: EXPERIMENTAL
Intervention: Second trimester weight gain trajectory
Number of subjects: 124590
Study 28151742 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain trajectory by prepregnancy BMI category
Number of subjects: 124590
Study 27052266 — intervention group
Group type: EXPERIMENTAL
Intervention: 4RIF (rifampin for 4 months)
Number of subjects: 189
Study 27052266 — intervention group
Group type: EXPERIMENTAL
Intervention: 9INH (isoniazid for 9 months)
Number of subjects: 189
Study 27052266 — intervention group
Group type: COMPARATOR
Intervention: TST positive
Number of subjects: 189
Study 27052266 — intervention group
Group type: COMPARATOR
Intervention: QFT-G positive
Number of subjects: 189
Study 27052266 — intervention group
Group type: COMPARATOR
Intervention: LTBI treatment acceptance
Number of subjects: 189
Study 25171686 — intervention group
Group type: EXPERIMENTAL
Intervention: intelligent volume-assured pressure support (iVAPS)
Number of subjects: 14
Study 25171686 — intervention group
Group type: COMPARATOR
Intervention: high-intensity noninvasive positive-pressure ventilation (HI-NPPV)
Number of subjects: 14
Study 21806683 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of undisturbed plaque accumulation
Number of subjects: 15
Study 21806683 — intervention group
Group type: COMPARATOR
Intervention: 3 weeks of optimal plaque control
Number of subjects: 15
Study 21806683 — intervention group
Group type: EXPERIMENTAL
Intervention: CF levels of MMP-8
Number of subjects: 15
Study 21806683 — intervention group
Group type: EXPERIMENTAL
Intervention: CF levels of IL-1β
Number of subjects: 15
Study 21806683 — intervention group
Group type: EXPERIMENTAL
Intervention: Total DNA counts
Number of subjects: 15
Study 21806683 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection frequency of putative periodontal pathogens
Number of subjects: 15
Study 20232769 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT with Phleum pratense
Number of subjects: 46
Study 20232769 — intervention group
Group type: COMPARATOR
Intervention: Control group without SIT
Number of subjects: 46
Study 17437728 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 479
Study 17437728 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus thienopyridine
Number of subjects: 479
Study 16416663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg IM one hr before surgery (Group A)
Number of subjects: 48
Study 16416663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg into the surgical site (Group B)
Number of subjects: 48
Study 16416663 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg IM one hr before surgery plus 50 mg into the surgical site (Group C)
Number of subjects: 48
Study 16416663 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 48
Study 12503833 — intervention group
Group type: EXPERIMENTAL
Intervention: SPO2 80%
Number of subjects: 12
Study 12503833 — intervention group
Group type: EXPERIMENTAL
Intervention: SPO2 90%
Number of subjects: 12
Study 12503833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SPO2 > 97%)
Number of subjects: 12
Study 9845561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg twice daily for 1 week
Number of subjects: 77